Icon

Beyaz - (3MG,N/A; 0.02MG,N/A; 0.451MG,0.451M; Tablet, Oral)

Drospirenone and Ethinyl Estradiol and Levomefolate Bayer
3MG,N/A; 0.02MG,N/A; 0.451MG,0.451M; Tablet, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
None
Less Than 5
Less Than 5
Indicated for use by women to prevent pregnancy.
Yes
****** *** *** ***** ** **** **** ** **** ****** *******- **** **, **** *** *** ************ *********. ***** ***** *** ****** ** ***** *** *********. ****** ******** *** ******** ** ******* ******* *** ******* ******* ******** ******** *****'* ******** *** ***** *** ****** ** *******. ********* ***** ***** **** ** **** *** **** ****** *** *** ************ *********. ***** ******** *** ******** ** ******* ***** ***** ******* ***** **** ***** *** ****** ** *******. ****** ******** ******** *** ******** *** *******. ********* **** ****** ** ******* *** *******.
Beyaz Patent 1 Patent 2 Patent 3 Patent 4
****** *** ** ** ***** ********** ******* ******* *******
***** *** ** ** ***** ********** ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ *** *** **, **** *** ** ** ***** ********** ******** ******** ** *** **, ****
***** ** \ ** ***** *, **** *** ** ** ***** ********** ******** ******** ** *** **, ****
  1. *** *, **** : ****** ******** ***** ***** *** **** ** **** ****** '*** (**** **, ****).
  2. *** **, **** : ***** & *** *** ***** ***** * **** ******* ****** ** ******** ***** ** ********.
  3. *** **, **** : ********** ********* **** ******
  4. *** **, **** : ***** ***** **** ****** '*** ** *****. ****** ******** *** ******** ** ******* *******.
  5. *** **, **** : ***** ******** ***** *** **** ** **** ***** *** ****** '*** (**** **, ****).
  6. *** **, **** : ***** ***** * **** ******* ***** ** ******** ***** ** ********.
  7. *** **, **** : ********** ********* **** *****
  8. *** **, **** : ******* ******* ******** ******** ***** ****** ******* **** '*** ****** ** *******.
  9. *** **, **** : ***** ******** *** ******** ** ******* *****.
  10. *** **, **** : ******* ***** ******** ******* *******'* ****** *** ****** *** ****** ** ** *****. ***** ** ******** *** ********
  11. *** *, **** : ******* ***** **-******** *** ********.
  12. *** **, **** : ****** ******** ******* ***** ** **
  13. *** **, **** : ***** ******** ******* ***** ** **

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.